Citadel Advisors’s Pactiv Evergreen Inc. Common stock PTVE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-95,600
Closed -$1.72M 15793
2025
Q1
$1.72M Buy
95,600
+69,600
+268% +$1.24M ﹤0.01% 5827
2024
Q4
$454K Buy
26,000
+18,500
+247% +$250K ﹤0.01% 8771
2024
Q3
$86.3K Sell
7,500
-4,700
-39% -$53.9K ﹤0.01% 11315
2024
Q2
$138K Buy
12,200
+5,400
+79% +$71.8K ﹤0.01% 10467
2024
Q1
$97.4K Buy
6,800
+2,300
+51% +$32.6K ﹤0.01% 11393
2023
Q4
$61.7K Buy
4,500
+3,400
+309% +$35.8K ﹤0.01% 11563
2023
Q3
$8.94K Sell
1,100
-100
-8% -$817 ﹤0.01% 13154
2023
Q2
$9.08K Buy
1,200
+900
+300% +$6.87K ﹤0.01% 13272
2023
Q1
$2.4K Sell
300
-9,800
-97% -$101K ﹤0.01% 14153
2022
Q4
$115K Sell
10,100
-700
-6% -$7.64K ﹤0.01% 11029
2022
Q3
$94K Buy
+10,800
New +$112K ﹤0.01% 11148

Citadel Advisors's PTVE Position: Q2 2025 in Review

Citadel Advisors sold out of Pactiv Evergreen Inc. Common stock (PTVE) in Q2 2025, closing a stake of 132,475 shares — an estimated $2.39M sold.

Citadel Advisors first reported a position in PTVE in Q3 2020 and held it in 17 quarters. The position peaked at $2.41M in Q2 2023. 0 funds tracked by Wall St. Rank hold PTVE as of Q2 2025.

  • Citadel Advisors reported no remaining Pactiv Evergreen Inc. Common stock position as of Q2 2025 after selling out during the quarter.
  • Citadel Advisors sold 132,475 Pactiv Evergreen Inc. Common stock shares in Q2 2025, an estimated $2.39M.
  • Citadel Advisors first reported a position in Pactiv Evergreen Inc. Common stock in Q3 2020 and held it in 17 quarters.
  • Citadel Advisors's Pactiv Evergreen Inc. Common stock position peaked at $2.41M in Q2 2023.
  • 0 funds tracked by Wall St. Rank held Pactiv Evergreen Inc. Common stock as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.